PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circ Cardiovasc Genet. Author manuscript; available in PMC 2012 December 1.
Published in final edited form as:
PMCID: PMC3293207
NIHMSID: NIHMS340747

Association of Genetic Variants and Incident Coronary Heart Disease in Multi-Ethnic Cohorts. The PAGE Study

Abstract

Background

Genome wide association studies identified several single nucleotide polymorphisms (SNPs) associated with prevalent coronary heart disease (CHD) but less is known of associations with incident CHD. The association of thirteen published CHD SNPs was examined in five ancestry groups of four large US prospective cohorts.

Methods and Results

The analyses included incident coronary events over 9.1 to 15.7 average follow-up times in up to 26,617 white individuals (6,626 events), 8,018 African Americans (914 events), 1,903 Hispanics (113 events), 3,669 American Indians (595 events) and 885 Asian/Pacific Islanders (66 events). We used Cox proportional hazards models (with additive mode of inheritance) adjusted for age, sex and ancestry (as needed). Nine loci were statistically associated with incident CHD events in whites: 9p21 (rs10757278, p=4.7 × 10−41), 16q23.1 (rs2549513, p=0.0004), 6p24.1 (rs499818, p=0.0002), 2q36.3 (rs2943634, p=6.7 × 10−6), MTHFDIL (rs6922269, p=5.1 × 10−10), APOE (rs429358, p=2.7 × 10−18), ZNF627 (rs4804611, p=5.0 × 10−8), CXCL12 (rs501120, p=1.4 × 10−6) and LPL (rs268, p=2.7 × 10−17). The 9p21 region showed significant between-study heterogeneity, with larger effects in individuals aged 55 years or younger and in women. Inclusion of coronary revascularization procedures among the incident CHD events introduced heterogeneity. The SNPs were not associated with CHD in African Americans and associations varied in other US minorities.

Conclusions

Prospective analyses of white individuals replicated several reported cross-sectional CHD-SNP associations.

Keywords: 9p21 locus, incident coronary heart disease, genetic polymorphisms

Recent genome wide association studies (GWAS) identified several single nucleotide polymorphisms (SNPs) in genes or regions associated with coronary heart disease (CHD). Most were retrospective case-control comparisons and little is known about the contribution of these genetic variants to the risk of incident CHD in the general population.

One of the loci most studied for CHD is the 9p21 region near the CDKN2A-2B genes. This 58 kb region, in high linkage disequilibrium (LD) in individuals of European ancestry, overlaps a large noncoding RNA (antisense noncoding RNA in the INK locus – ANRIL), which may contribute to atherosclerosis through regulatory function on the CDKN2A-2B genes1. In addition to clinical CHD, variants in the 9p21 region (i.e., rs10757274 and rs2383206) have shown associations with coronary artery calcification2, 3, premature atherosclerosis2, ischemic stroke 4, heart failure 5, peripheral artery disease6, abdominal aortic aneurysm and intracranial aneurysm 7 in white populations. Helgadottir et al reported early age of onset effects for CHD for this locus8. A recent meta-analysis of 22 studies including 35,872 cases and 95,837 controls, mostly whites, also suggested a larger effect (magnitude of association) of 9p21 variants in studies with earlier age of onset of clinical CHD9. Generalization of the genetic effects of this locus to populations of Asian ancestry was also observed in the latter meta-analysis.

A limited number of prospective studies of CHD have replicated the associations of the 9p21 region with incident CHD in white individuals, such as participants of the Atherosclerosis Risk in Communities (ARIC) study2. However, the associations did not replicate in studies of African Americans, including the ARIC study participants 2, 10 although it must be noted that the number of observations was suboptimal in several of these studies 3. To our knowledge, a meta-analysis of the association of the 9p21 locus with incident CHD in other US minorities has not been done. We also note that additional loci for CHD have been recently described 11-13(CELSR2/PSRC1, MTHFD1L, MIA3 among others); these associations have not been replicated in US minorities.

The Population Architecture using Genomics and Epidemiology (PAGE) Study enables a comprehensive analysis of the association of previously validated CHD variants with incident CHD in data from multiple prospective cohort studies, diverse cultural, ancestral and socio-economic settings. We examined whether CHD-related SNPs are associated with incident CHD in individuals of European ancestry in PAGE, and evaluated whether these SNPs are associated with incident CHD in US minorities, specifically in individuals self-identified as African American, American Indian, Hispanic and Asian/Pacific Islanders.

Methods

Population and definition of CHD events

The PAGE Study includes four large ongoing NIH-funded population based studies or consortia: EAGLE (Epidemiologic Architecture for Genes Linked to Environment, based on three National Health and Nutrition Examination Surveys 14, NHANES), MEC (the Multiethnic Cohort study15), WHI (Women’s Health Initiative16), and CALiCo (Causal Variants Across the Life Course, a consortium of 5 cohort studies: Atherosclerosis Risk in Communities (ARIC)17, Coronary Artery Risk in Young Adults [CARDIA]18, Cardiovascular Health Study [CHS]19, Hispanic Community Health Study/Study of Latinos [HCHS/SOL], and Strong Heart Study [SHS] 20, 21). This report is based on prospective data on incident CHD from the ARIC, CHS, SHS and WHI studies. Fatal and non-fatal incident CHD events were defined as acute myocardial infarction (MI), fatal CHD, ECG diagnosis of MI (except in the WHI), and/or documented coronary revascularization procedures, based on record abstraction and confirmed by a panel of physician reviewers. Prevalent cases of CHD at the respective baseline visits were excluded.

The design of the parent studies has been previously described. Briefly, the ARIC study is a multi-center prospective investigation of atherosclerotic disease in a bi-racial population (white and African Americans).17 ARIC recruited 15,792 individuals aged 45-64 years from four communities for a baseline examination in 1987-1989, with follow-up examinations in approximate 3-year intervals, during 1990-1992, 1993-1995, and 1996-1998. CHD events were ascertained from annual follow-up morbidity and mortality surveillance including hospitalizations and deaths. Events were reviewed by two physicians and differences adjudicated. CHD events were defined as non-fatal acute (definitive or probable) MI, fatal CHD and coronary revascularization procedures (coronary angioplasty or coronary artery bypass graft) through December 31st, 2005. All subjects provided written informed consent. CHS is a population-based cohort study of risk factors for CHD and stroke in adults ≥65 years conducted across four field centers in the United States 19. The original predominantly Caucasian cohort of 5201 persons was recruited in 1989-1990 from a random sample of people on Medicare eligibility lists and 687 African-Americans were enrolled subsequently in 1991-1992 for a total sample of 5888. CHS participants completed standardized clinical examinations and questionnaires at study baseline and 9 annual follow-up visits. Follow-up for clinical events occurred every 6 months. CHD was classified by the CHS endpoints committee; suspected events were further investigated by a physician review panel. CHD events were defined as nonfatal MI, coronary artery angioplasty, coronary bypass surgery, or CVD death caused by “atherosclerotic CHD”. CHD follow-up was available through June 30, 2007. SHS recruited 4,549 American Indians aged 45 to 74 years from 1989 to 1992 from 13 tribes at three study centers: Oklahoma, North and South Dakota and Arizona 20. Events were determined from medical records, autopsy reports, and informant interviews; all materials were independently reviewed by physician members of the SHS study’s morbidity and mortality committees. CHD events were defined by the occurrence of nonfatal definite MI, definite CHD, ECG-evident definite MI, fatal definite MI, definite CHD, and sudden death. Follow-up went from 1989-91 through December 31st, 2006. The Indian Health Service Institutional Review Board and institutional review boards of the participating institutions and participating tribes approved the study; informed consent was obtained from all participants. WHI is a prospective cohort study investigating post-menopausal women’s health in the U.S 16. A total of 161, 838 women aged 50–79 years old were recruited from 40 US clinical centers between 1993 and 1998 to participate in the observational study (OS) and in clinical trials (CT): postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary modification trial 16. Study protocols and consent forms were approved by the institutional review boards at all participating institutions. Annual (OS) and semi-annual (CT) follow-up identifies self-reported events which are then adjudicated following medical record review 22. CHD was defined as acute (definitive or probable) MI requiring overnight hospitalization, fatal CHD or coronary revascularization (coronary angioplasty or coronary artery bypass graft) procedures. Acute MI was determined according to standardized criteria that included cardiac pain, cardiac enzyme (and troponin levels) and ECG readings. Events as of August 2009 are included in these analyses. A subset of 21,000 WHI women was selected for genotyping and for inclusion in the current study. Women were selected based on self-reported history of disease, incident event outcomes, DNA availability and consent, and racial/ethnic diversity. Follow-up was through August 2009.

SNP selection and Genotyping

SNPs (in genes or regions) were identified from published GWAS for their association with CHD and those available as per January 2009 were genotyped in PAGE studies 23-28. SNPs were available in at least one study for the following loci: the 9p21 region near the CDKN2A-2B gene (rs1333049, rs2383207, rs10757274), CELSR2/PSRC1/SORT1 (rs599839), SMAD3 (rs17228212), 6p24.1 (rs499818), 16q23.1 (rs2549513), MIA3 (rs17465637), MTHFD1L (rs6922269), 2q36.3 (rs2943634), APOE (rs429358, rs7412), ZNF627 (rs4804611), CXCL12 (rs501120), LPL (rs268) and PCSK9 (rs11206510). We examined the correlation among SNPs in the same region using pair-wise r2 and D’ statistics29 for linkage disequilibrium (LD). For three SNPs located in the 9p21 region (rs10757278, rs1333049, rs2383207) in African Americans (ARIC) and in the American Indians (SHS), the correlation among SNPs was 0.85 or more in African Americans and in American Indians (Supplemental Figures 1A-D). Therefore, we only reported associations for one SNP in the region (rs10757278). For the two APOE SNPs, correlation was 0.99 in all ethnicities and therefore we reported only associations for rs429358.

Genotyping was performed in two centers: the CALiCo Core Genotyping Laboratory at Human Genetics Center The University of Texas (Houston, TX) genotyped samples from ARIC, CHS and SHS using Taqman assays (Applied Biosystems); the Translational Genomics Research Institute (Phoenix, AZ) genotyped WHI samples using Illumina’s Veracode GoldenGate genotyping assays. Each laboratory genotyped 360 HapMap samples for cross-lab and cross-platform quality control. Quality control assessments included sample call rates (> 95%), concordance of blinded replicates (>98%) and deviation from Hardy-Weinberg equilibrium among controls within self-reported ethnic group (p<0.01). In CALiCo populations with prior GWAS characterization (ARIC and CHS), genotyped SNPs were used (Affymetrix 6.0 for ARIC and Illumina Human 370CNV BeadChip )30. Quality control for GWAS has been described30. All alleles were aligned to positive strands.

Statistical analysis

All analyses were stratified by study and self-reported ethnicity. Cox proportional hazard models (implemented in SAS 9.2 using Proc PHREG procedure or in R)31 were used to estimate ethnic-specific associations of SNPs with CHD (hazard ratios, HR, and 95% confidence intervals) while adjusting for baseline levels of covariates age and sex, study site (as applicable) and population stratification. We also performed an analysis adjusting for body mass index (BMI), ever smoking, type 2 diabetes, systolic blood pressure, blood pressure-lowering medication use and education (12 years or equivalent versus less than 12 years). Results were unchanged in fully adjusted models and therefore we report minimally adjusted models except for 9p21 region in whites. Lipid measures were only available in a subset of women in the WHI and therefore were not included in analyses. To explore phenotypic heterogeneity as described by Kitsios et al.32, we also performed sensitivity analyses using an alternative CHD definition which included only fatal CHD and non-fatal MI.

PAGE studies used the following strategies to adjust for population stratification: ARIC whites and WHI used principal components (PC) estimated from pre-existing GWAS data, adjusting only for PCs significantly associated with the outcome (alpha=0.05). For ARIC African Americans a set of 1536 ancestry informative markers genotyped among 3965 black ARIC participants was used to derive mean percentage of European ancestry using the software ANCESTRYMAP 33. This variable was included as a covariate in the regression analyses. SHS used self-reported percentage of Indian blood.

All analyses used additive genetic models as described in the initial publications for these SNPs and/or the replication studies in whites. WHI used weighted analyses to account for the sampling schema, with sample weights ranging from 1 to 60.4. The study-specific log(HR) estimates were combined within each ethnicity using inverse-weighted variance meta-analyses34. Summary estimates and 95% confidence intervals (CI) are reported. A nominal replication was considered a p-value < 0.05 and a Bonferroni adjusted replication was considered p-value < 0.0008 (13 SNPs and 5 races for an α=0.05).We also tested for evidence of between-study heterogeneity 35 by estimating the between-study variance and the I2 metric, which is a measure of the percentage of the total variation across studies due to heterogeneity rather than chance 36. For the 9p21 SNP association, which showed significant between-study heterogeneity (p-value<0.10), we performed stratified analyses by age and sex.

We also constructed an additive genetic risk score (0-18 alleles) comprising the number of risk alleles at the nine loci showing significant replication in white individuals (p<0.0008) using data from the following SNPs (coded allele): rs10757278 (G), rs2549513(A), rs499818(A), rs6922269(A), rs429358(C), rs4804611(A), rs501120(T), rs268(G) and rs2943634(C). We then tested the association of categories or continuous risk scores with incident CHD in WHI, the study that had data on all the SNPs.

For associations in samples of US minorities, we estimated power assuming an additive genetic effect, magnitude of effect estimate of reported associations in white individuals, an alpha = 0.05, a two-sided test, and population baseline prevalence of 0.10 (Quanto v.1.2.4).

Results

Associations with incident CHD events were examined in the prospective cohorts of whites (up to 26,617 individuals and 6,626 events), African Americans (8,018 individuals and 914 events), Hispanics (1,903 individuals and 113 events), American Indians (3,669 individuals and 595 events) and Asian/Pacific Islanders (885 individuals and 66 events). The mean follow-up of studies varied from 9.1 to 15.7 person-years (Supplemental Table 1). CHS participants were older than individuals in other studies and WHI recruited only women (Table 1). CHD risk factors varied across studies and ethnicities.

Table 1
Study characteristics by self-reported race/ethnicity

We first evaluated replication of SNP associations with incident CHD in samples of white individuals. Nine of 13 investigated loci associations showed replication by our a priori criteria (p<0.0008) including the 9p21 region (Table 2), 16q23.1 (rs2549513, p=0.0004), 6p24.1 (rs499818, p=0.0002), MTHFDIL (rs6922269, p=5.1 × 10−10), 2q26.3 (rs2943634, p=6.7 × 10−6), APOE (rs429358, p=2.7 × 10−18), ZNF627 (rs4804611, p=5.0 × 10−8), CXCL12 (rs501120, p=1.4 × 10−6) and LPL (rs268, p=2.7 × 10−17) (Table 3). Meta-analyses including incident findings from published variants in the ARIC study are shown in Supplemental Table 2. Replicated loci had similar direction and magnitude of effects as reported. Using an additive genetic score from these nine SNPs, we observed an increased hazard of CHD across increasing categories of genetic risk score (Table 5). CELSR2/SORT, MIA3 and SMAD3 SNPs were not associated with incident events in white individuals.

Table 2
Study-specific and meta-analysis findings in white individuals for the association of rs10757278 (9p21 locus) with incident coronary heart disease using different event definitions
Table 3
Replication of associations in white individuals for additional coronary heart disease loci
Table 5
Additive genetic score comprised of eight significant single nucleotide polymorphisms and the risk of incident coronary heart disease in white individuals

In the 9p21 region the proxy SNP rs10757278 had associations of similar direction and magnitude as in published studies, but we noted significant between-study heterogeneity at this locus (Table 2). Each copy of the rs10757278 G allele was associated with increased hazard of CHD that varied from 10% (CHS) to 22% (WHI) (p for heterogeneity = 0.03, I2=71.5%). Study-specific cumulative incidence findings by genotypes are shown in Supplemental Table 3. Estimates were unchanged in analyses adjusted for multiple CHD risk factors (Table 2). Sex-specificity and the varying age at recruitment were investigated as possible sources of the heterogeneity of effects. The hazard ratios for CHD by decade of age at study recruitment summarized in Figure 1A show a notably greater risk of CHD for individuals 55 years or younger. The magnitude of the risk estimates decreased with increasing decade of age, although large heterogeneity remained across age-strata (Figure 1A, Supplemental Table 4). In sex-specific analysis the CHD hazard was greater in women compared to men, with large between-sex heterogeneity of effects (Figure 1B, Supplemental Table 5). In analyses stratified by age and sex, the risk of CHD was greater in women than men at earlier ages (Figure 1C and Supplemental Table 6). To investigate CHD phenotypic heterogeneity due to inclusion of revascularization procedures, we performed sensitivity analyses using only non-fatal MI and CHD fatal events. Between-study heterogeneity for the CHD associations of rs10757278 was no longer present in these analyses (Table 2). Supplemental Table 7 shows the findings using this definition for additional loci showing heterogeneity.

Figure 1A-CFigure 1A-CFigure 1A-C
Meta-analysis results of the association of rs10757278 9p21 variant by age of study recruitment (A), sex (B) and age and sex strata (C).

We also examined whether SNP associations with CHD generalize to samples of US minority groups (Tables 4). Because of high correlation between the SNPs in the 9p21 region in African Americans and SHS American Indians (Supplemental Figures 1A-D), we only report findings for rs10757278. The association of rs10757278 with incident CHD did not replicate in African Americans despite large sample sizes and greater than 80% power to detect an effect of similar magnitude to whites (Table 4). SNPs in the 9p21 region were nominally associated with CHD in American Indians with similar magnitude and direction of effect as in whites. However, we also observed significant between-study heterogeneity of effect across the four groups of American Indians, as well as in analyses including only SHS participants (Table 4). We were unable to evaluate the associations in the 9p21 region in Hispanics and Asian/Pacific Islander due to limited sample sizes. Other loci showing nominal associations in minorities are shown in Table 4.

Table 4
Associations of coronary heart disease loci in US minorities

Discussion

Replication of the association of SNPs in the 9p21 region with incident CHD was found in white individuals, as well as generalization of these associations to American Indians but not to African Americans, Hispanics or Asian/Pacific Islanders. Our study size was limited for Hispanics and Asians but prior studies have shown associations of this region with CHD in Pakistanis (1851 MI cases and 1903 controls) 37, Han Chinese (510 CHD cases and 557 controls) 38, Japanese and Koreans 39, 40 and US Hispanics (82 cases and 108 controls)3. This locus has been recently shown to disrupt a transcription-factor-biding site involved in the inflammatory response (STAT1) which affects the expression of the CDKN2A-2B genes 41. Consistent with previously reports, we identified age- and sex-specific effects for the 9p21 locus on CHD risk. The rs10757278 G risk variant showed a larger effect in younger compared to older cohort participants, more evident for individuals aged 55 years or younger and in women. Heterogeneity in the estimates for 9p21 in white individuals persisted even after adjusting for multiple risk factors for CHD, but was no longer present in analyses that excluded revascularization procedures from the definition of incident CHD events. Because the use of CHD revascularization procedures (coronary angioplasty or coronary artery bypass graft) may vary in subgroups of individuals due to indication (younger symptomatic individuals and men are more likely to be offered procedures) and to socio-economic factors (access to care), our results highlight the importance of using strict and homogeneous definition of CHD events when combining data from multiple studies for evaluation of genetic effects. Thus, our results do not support sex- and age-specific effects for 9p21 locus for incident CHD.

We were able to replicate multiple other loci in white individuals including MTHFD1L, 16q23.1, 6p24.1, 2q36.3, APOE, ZNF627, CXCL12 and LPL. Most of these loci were initially identified in the Welcome Trust Case Control Consortium (WTCCC) 24. In general, we noticed a modestly greater CHD risk in our prospective analysis compared to the magnitude of association described using a case-control design in prior studies 24, 28, 42. However, the risk score using these variants showed consistent graded increased CHD risk. In addition, we found significant between-study heterogeneity for the MTHFD1L and CXCL12 loci (Supplemental Table 2), similarly to findings recently described in the case-control meta-analysis of the CARDIoGRAM consortium for the MTHFD1L associations 42.

The direction of effect of the remaining SNPs evaluated in whites was consistent with those in the discovery studies. Interestingly, three loci, CELSR2/SORT1, MIA3 and PCSK9, which have been associated with early-onset MI in whites28, did not replicate in our study and in a recently published study of Finland and Sweden individuals43 . Recent experimental evidence suggests a role of SORT1 product, sortilin 1, in the hepatic metabolism of lipoproteins containing apolipoprotein B 44. We had over 80% power to detect an effect for this locus in whites, assuming effects similar in magnitude to those published. Because our incident cases were first CHD events occurring after age 45 and the studies that identified these SNPs were cases of early MI compared to controls, our negative findings are not inconsistent with the previously reported associations in white individuals.

None of the SNPs tested was significantly associated with CHD in African Americans after adjustments for multiple testing and our samples in Hispanics and Asians were limited preventing conclusions. SNPs in the 9p21 region available for this analysis are highly correlated (r2>0.85) in African Americans. However, the genotyped SNPs may not be ideal proxy for functional SNPs in the region for populations of recent African ancestry. In addition, three other well powered SNP associations (rs599839, rs6922269 and rs2943634) were not significant in African Americans. Testing additional SNPs at these and other loci may help to elucidate if LD patterns account for some of the negative findings in African Americans.

The strengths of this study are the prospective evaluation of the genetic effect on CHD risk in large population based studies and the multi-ethnic evaluation of CHD loci. Our analyses were limited to SNPs previously identified in individuals of European ancestry, reported by January 2009, when SNP selection was done for genotyping in PAGE. Therefore, we did not evaluate recently discovered variants and we were unable to evaluate race-specific variants in these loci which will require fine mapping of the regions.

In summary, we identified significant heterogeneity of the 9p21 locus and other loci in individuals of European ancestry in prospective analyses of CHD risk, some of which could be explained by differences in event definition. Overall, some SNP associations replicated in longitudinal analysis of white individuals but effects were modest and none of the SNPs was associated with incident CHD in large sample sizes of African Americans. Fine-mapping of these regions may help to clarify these negative findings.

Supplementary Material

Acknowledgments

Funding Sources: The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo), U01HG004798 (EAGLE), U01HG004802 (MEC), U01HG004790 (WHI), and U01HG004801 (Coordinating Center). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The complete list of PAGE members can be found at http://www.pagestudy.org.

The data and materials included in this report result from collaborations between the following studies: Funding support for the “Epidemiology of putative genetic variants: The Women’s Health Initiative” study is provided through the NHGRI PAGE program (U01HG004790). The WHI program is funded by the National Heart, Lung, and Blood Institute; NIH; and U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whiscience.org/publications/ WHI_investigators_shortlist.pdf .

Funding support for the Genetic Epidemiology of Causal Variants Across the Life Course (CALiCo) program was provided through the NHGRI PAGE program (U01HG004803). The following studies contributed to this manuscript and are funded by the following agencies: The Atherosclerosis Risk in Communities (ARIC) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022. The Coronary Artery Risk Development in Young Adults (CARDIA) study is supported by the following National Institutes of Health, National Heart, Lung and Blood Institute contracts: N01-HC-95095; N01-HC-48047; N01-HC-48048; N01-HC-48049; N01-HC-48050; N01-HC-45134; N01-HC-05187; and N01-HC-45205. The Cardiovascular Health Study (CHS) is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grants U01HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. CHS GWAS DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The Strong Heart Study (SHS) is supported by NHLBI grants U01 HL65520, U01 HL41642, U01 HL41652, U01 HL41654, and U01 HL65521. The opinions expressed in this paper are those of the author(s) and do not necessarily reflect the views of the Indian Health Service.

Assistance with phenotype harmonization, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by the PAGE Coordinating Center (U01HG004801-01). The National Institutes of Mental Health also contributes to the support for the Coordinating Center.

The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions.

Footnotes

Conflict of Interest Disclosures: None

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409–412. [PMC free article] [PubMed]
2. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491. [PMC free article] [PubMed]
3. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic advance study. Hum Mol Genet. 2008;17:2320–2328. [PMC free article] [PubMed]
4. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke. 2008;39:1586–1589. [PubMed]
5. Yamagishi K, Folsom AR, Rosamond WD, Boerwinkle E. A genetic variant on chromosome 9p21 and incident heart failure in the aric study. Eur Heart J. 2009;30:1222–1228. [PMC free article] [PubMed]
6. Cluett C, McDermott MM, Guralnik J, Ferrucci L, Bandinelli S, Miljkovic I, Zmuda JM, Li R, Tranah G, Harris T, Rice N, Henley W, Frayling TM, Murray A, Melzer D. The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ Cardiovasc Genet. 2009;2:347–353. [PMC free article] [PubMed]
7. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, Jaaskelainen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsater A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsdottir E, Walters GB, Jonsdottir T, Snorradottir S, Magnusdottir D, Gudmundsson G, Ferrell RE, Sveinbjornsdottir S, Hernesniemi J, Niemela M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, Teijink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadottir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thorgeirsson G, Kong A, Thorsteinsdottir U, Stefansson K. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–224. [PubMed]
8. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–1493. [PubMed]
9. Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: A meta-analysis. Jama. 2010;303:648–656. [PubMed]
10. Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a european genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities study. Am J Epidemiol. 2010;171:14–23. [PMC free article] [PubMed]
11. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–169. [PubMed]
12. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240–1249. [PubMed]
13. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 european population cohorts. Nat Genet. 2009;41:47–55. [PMC free article] [PubMed]
14. Statistics. NCfH. Plan and operation of the third national health and nutrition examination survey, 1988-94. 1994. [PubMed]
15. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in hawaii and los angeles: Baseline characteristics. Am J Epidemiol. 2000;151:346–357. [PubMed]
16. Design of the women’s health initiative clinical trial and observational study. The women’s health initiative study group. Control Clin Trials. 1998;19:61–109. [PubMed]
17. The atherosclerosis risk in communities (aric) study: Design and objectives. The aric investigators. Am J Epidemiol. 1989;129:687–702. [PubMed]
18. Hughes GH, Cutter G, Donahue R, Friedman GD, Hulley S, Hunkeler E, Jacobs DR, Jr., Liu K, Orden S, Pirie P, et al. Recruitment in the coronary artery disease risk development in young adults (cardia) study. Control Clin Trials. 1987;8:68S–73S. [PubMed]
19. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The cardiovascular health study: Design and rationale. Ann Epidemiol. 1991;1:263–276. [PubMed]
20. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV. The strong heart study. A study of cardiovascular disease in american indians: Design and methods. Am J Epidemiol. 1990;132:1141–1155. [PubMed]
21. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, MacCluer JW. Genetic and environmental contributions to cardiovascular disease risk in american indians: The strong heart family study. Am J Epidemiol. 2003;157:303–314. [PubMed]
22. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S. Outcomes ascertainment and adjudication methods in the women’s health initiative. Ann Epidemiol. 2003;13:S122–128. [PubMed]
23. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678. [PMC free article] [PubMed]
24. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–453. [PMC free article] [PubMed]
25. Larson MG, Atwood LD, Benjamin EJ, Cupples LA, D’Agostino RB, Sr., Fox CS, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Murabito JM, Newton-Cheh C, O’Donnell CJ, Seshadri S, Vasan RS, Wang TJ, Wolf PA, Levy D. Framingham heart study 100k project: Genome-wide associations for cardiovascular disease outcomes. BMC Med Genet. 2007;8(Suppl 1):S5. [PMC free article] [PubMed]
26. Sagoo GS, Tatt I, Salanti G, Butterworth AS, Sarwar N, van Maarle M, Jukema JW, Wiman B, Kastelein JJ, Bennet AM, de Faire U, Danesh J, Higgins JP. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: A huge association review and meta-analysis. Am J Epidemiol. 2008;168:1233–1246. [PubMed]
27. Song Y, Stampfer MJ, Liu S. Meta-analysis: Apolipoprotein e genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137–147. [PubMed]
28. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O’Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonzin P, Piazza A, Yee J, Friedlander Y, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Meigs JB, Williams G, Nathan DM, MacRae CA, Havulinna AS, Berglund G, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Daly MJ, Nemesh J, Korn JM, McCarroll SA, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burtt N, Gabriel SB, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS, Linsel-Nitschke P, Lieb W, Ziegler A, Konig I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Ouwehand W, Deloukas P, Scholz M, Cambien F, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Scheffold T, Berger K, Huge A, Martinelli N, Olivieri O, Corrocher R, McKeown P, Erdmann E, Konig IR, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Do R, Xie C, Siscovick D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–341. [PMC free article] [PubMed]
29. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. Nat Rev Genet. 2004;5:89–100. [PubMed]
30. Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E. Cohorts for heart and aging research in genomic epidemiology (charge) consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2:73–80. [PMC free article] [PubMed]
31. Breslow NE. Discussion of professor cox’s paper. J. Royal Stat. Soc. B. 1972;34:216–217.
32. Kitsios GD, Dahabreh IJ, Trikalinos TA, Schmid CH, Huggins GS, Kent DM. Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies. Circ Cardiovasc Genet. 2011;4:58–67. [PMC free article] [PubMed]
33. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O’Brien SJ, Altshuler D, Daly MJ, Reich D. Methods for high-density admixture mapping of disease genes. Am J Hum Genet. 2004;74:979–1000. [PubMed]
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. [PubMed]
35. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations. PLoS One. 2007;2:e841. [PMC free article] [PubMed]
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. [PMC free article] [PubMed]
37. Saleheen D, Alexander M, Rasheed A, Wormser D, Soranzo N, Hammond N, Butterworth A, Zaidi M, Haycock P, Bumpstead S, Potter S, Blackburn H, Gray E, Di Angelantonio E, Kaptoge S, Shah N, Samuel M, Janjua A, Sheikh N, Haider SR, Murtaza M, Ahmad U, Hakeem A, Memon MA, Mallick NH, Azhar M, Samad A, Rasheed SZ, Gardezi AR, Memon NA, Ghaffar A, Fazal Ur R, Zaman KS, Kundi A, Yaqoob Z, Cheema LA, Qamar N, Faruqui A, Jooma R, Niazi JH, Hussain M, Kumar K, Saleem A, Daood MS, Memon F, Gul AA, Abbas S, Zafar J, Shahid F, Memon Z, Bhatti SM, Kayani W, Ali SS, Fahim M, Ishaq M, Frossard P, Deloukas P, Danesh J. Association of the 9p21. 3 locus with risk of first-ever myocardial infarction in pakistanis. Arterioscler Thromb Vasc Biol. 2010;30:1467–1473. [PubMed]
38. Ding H, Xu Y, Wang X, Wang Q, Zhang L, Tu Y, Yan J, Wang W, Hui R, Wang CY, Wang DW. 9p21 is a shared susceptibility locus strongly for coronary artery disease and weakly for ischemic stroke in chinese han population. Circ Cardiovasc Genet. 2009;2:338–346. [PubMed]
39. Hiura Y, Fukushima Y, Yuno M, Sawamura H, Kokubo Y, Okamura T, Tomoike H, Goto Y, Nonogi H, Takahashi R, Iwai N. Validation of the association of genetic variants on chromosome 9p21 and 1q41 with myocardial infarction in a japanese population. Circ J. 2008;72:1213–1217. [PubMed]
40. Hinohara K, Nakajima T, Takahashi M, Hohda S, Sasaoka T, Nakahara K, Chida K, Sawabe M, Arimura T, Sato A, Lee BS, Ban JM, Yasunami M, Park JE, Izumi T, Kimura A. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in japanese and korean populations. J Hum Genet. 2008;53:357–359. [PubMed]
41. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, Frazer KA. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470:264–268. [PMC free article] [PubMed]
42. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O’Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–338. [PMC free article] [PubMed]
43. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses. Lancet. 2010;376:1393–1400. [PMC free article] [PubMed]
44. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser N, Ruda VM, Pirruccello JP, Muchmore B, Prokunina-Olsson L, Hall JL, Schadt EE, Morales CR, Lund-Katz S, Phillips MC, Wong J, Cantley W, Racie T, Ejebe KG, Orho-Melander M, Melander O, Koteliansky V, Fitzgerald K, Krauss RM, Cowan CA, Kathiresan S, Rader DJ. From noncoding variant to phenotype via sort1 at the 1p13 cholesterol locus. Nature. 2010;466:714–719. [PMC free article] [PubMed]